专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US4702977A Secondary battery using non-aqueous solvent 失效
标题翻译：二次电池使用非水溶剂
公开(公告)号：US4702977A
公开(公告)日：1987-10-27
申请号：US855826
申请日：1986-04-24
申请人： Kazuya Hiratsuka , Yuichi Sato , Yoshiyasu Aoki , Hiroshi Yui , Mitsutaka Miyabayashi , Akira Itsubo
发明人： Kazuya Hiratsuka , Yuichi Sato , Yoshiyasu Aoki , Hiroshi Yui , Mitsutaka Miyabayashi , Akira Itsubo
IPC分类号： H01M4/36 , H01M4/58 , H01M4/583 , H01M4/587 , H01M4/96 , H01M10/0525 , H01M10/36 , H01M4/38 , H01M10/40
CPC分类号： H01M4/583 , H01M10/0525 , H01M4/36 , H01M4/587
摘要： There is disclosed a secondary battery using a non-aqueous solvent which comprises using a carbonaceous material obtained by carbonating an organic compound and having a pseudographite structure of a hydrogen/carbon ratio being 0.15 or less, a d.sub.002 being 3.37 .ANG. or more and a Lc being 150 .ANG. or less as a negative electrode.The battery has a large electric density, less in self-discharging and excellent in preservability.
摘要翻译：公开了使用非水溶剂的二次电池，其包括使用通过碳酸化有机化合物获得的碳质材料，并且具有0.15或更小的氢/碳比的假型晶格结构，d002为3.37Ag或更大，Lc 作为负极为150A·cm以下。电池电量密度大，自放电少，保存性好。

2. 发明授权

US4767683A Non-aqueous electrochemical cell 失效
标题翻译：非水电化学电池
公开(公告)号：US4767683A
公开(公告)日：1988-08-30
申请号：US129902
申请日：1987-12-07
申请人： Shuji Yamada , Takahisa Ohsaki , Kiyoshi Mitsuyasu , Yuichi Sato , Yoshiyasu Aoki , Kazuya Hiratsuka
发明人： Shuji Yamada , Takahisa Ohsaki , Kiyoshi Mitsuyasu , Yuichi Sato , Yoshiyasu Aoki , Kazuya Hiratsuka
IPC分类号： H01M2/30 , H01M4/96 , H01M6/14 , H01M10/36
CPC分类号： H01M4/96 , H01M2/30 , H01M6/14
摘要： A non-aqueous electrochemical cell has an anode consisting of an element selected from the group consisting of lithium, sodium and aluminum; a cathode consisting of a porous carbon body and a current collector; and an electrolyte containing an oxyhalide, wherein the porous carbon body contains a carbon black having a structure wherein a thin layer of graphite crystals is formed on a surface of each of chain-like carbon black particles. The cell has a high discharge capacity and an excellent discharge efficiency in high rate discharge.
摘要翻译：非水电化学电池具有由选自锂，钠和铝的元素组成的阳极; 由多孔碳体和集电体组成的阴极; 以及含有卤氧化物的电解质，其中，所述多孔碳体含有碳黑，所述炭黑具有在链状炭黑粒子的表面上形成有石墨晶体的薄层的结构。电池具有高放电容量和高放电率的优异的放电效率。

3. 发明授权

US07374756B2 Specific binding agents for KSHV vIL-6 that neutralize a biological activity 失效
标题翻译：用于中和生物活性的KSHV vIL-6的特异性结合剂
公开(公告)号：US07374756B2
公开(公告)日：2008-05-20
申请号：US11803732
申请日：2007-05-14
申请人： Yoshiyasu Aoki , Giovanna Tosato
发明人： Yoshiyasu Aoki , Giovanna Tosato
IPC分类号： A61K39/395
CPC分类号： G01N33/56994 , A61K2039/505 , C07K16/085 , C07K16/248 , C12Q1/705 , G01N33/56983 , G01N33/6869 , G01N2333/03 , G01N2333/5412 , G01N2469/10 , G01N2500/00 , G01N2500/02 , G01N2500/04 , G01N2800/52 , C12Q2563/131
摘要： A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.
摘要翻译：提供特异性结合剂，其中特异性结合剂特异性结合卡波西肉瘤相关疱疹病毒（KSHV）白细胞介素-6（vIL-6），特异性结合剂中和vIL-6的活性。在一个实施方案中，特异性结合剂是抗体。提供了使用结合vIL-6的特异性结合剂并中和vIL-6的生物学活性的方法。还提供了KSHV相关疾病的治疗方法。提供了用于诊断KSHV相关疾病的方法，以及包括本发明的特异性结合剂的试剂盒。还提供了用于测试试剂以治疗KSHV相关病症的有效性的方法。该方法包括将试剂与包含vIL-6受体组分和vIL-6的无细胞系统一起孵育，并比较在试剂存在下vIL-6和受体组分与vIL-6与受体结合的结合组件在没有代理的情况下。在试剂存在下，vIL-6与受体成分的结合减少表明该试剂对于治疗KSHV相关病症是有效的。

4. 发明申请

US20080260687A1 SPECIFIC BINDING AGENTS FOR KSHV vIL-6 THAT NEUTRALIZE A BIOLOGICAL ACTIVITY 审中-公开
标题翻译： KSHV vIL-6特异性结合剂中和生物活性
公开(公告)号：US20080260687A1
公开(公告)日：2008-10-23
申请号：US12104326
申请日：2008-04-16
申请人： Yoshiyasu Aoki , Giovanna Tosato
发明人： Yoshiyasu Aoki , Giovanna Tosato
IPC分类号： A61K45/00 , G01N33/566 , A61P37/00
CPC分类号： G01N33/56994 , A61K2039/505 , C07K16/085 , C07K16/248 , C12Q1/705 , G01N33/56983 , G01N33/6869 , G01N2333/03 , G01N2333/5412 , G01N2469/10 , G01N2500/00 , G01N2500/02 , G01N2500/04 , G01N2800/52 , C12Q2563/131
摘要： A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.
摘要翻译：提供特异性结合剂，其中特异性结合剂特异性结合卡波西肉瘤相关疱疹病毒（KSHV）白细胞介素-6（vIL-6），特异性结合剂中和vIL-6的活性。在一个实施方案中，特异性结合剂是抗体。提供了使用结合vIL-6的特异性结合剂并中和vIL-6的生物学活性的方法。还提供了KSHV相关疾病的治疗方法。提供了用于诊断KSHV相关疾病的方法，以及包括本发明的特异性结合剂的试剂盒。还提供了用于测试试剂以治疗KSHV相关病症的有效性的方法。该方法包括将试剂与包含vIL-6受体组分和vIL-6的无细胞系统一起孵育，并比较在试剂存在下vIL-6和受体组分与vIL-6与受体结合的结合组件在没有代理的情况下。在试剂存在下，vIL-6与受体成分的结合减少表明该试剂对于治疗KSHV相关病症是有效的。

5. 发明授权

US07235365B2 Specific binding agents for KSHV vIL-6 that neutralize a biological activity 失效
标题翻译：用于中和生物活性的KSHV vIL-6的特异性结合剂
公开(公告)号：US07235365B2
公开(公告)日：2007-06-26
申请号：US11493687
申请日：2006-07-25
申请人： Yoshiyasu Aoki , Giovanna Tosato
发明人： Yoshiyasu Aoki , Giovanna Tosato
IPC分类号： C12Q1/68
CPC分类号： G01N33/56994 , A61K2039/505 , C07K16/085 , C07K16/248 , C12Q1/705 , G01N33/56983 , G01N33/6869 , G01N2333/03 , G01N2333/5412 , G01N2469/10 , G01N2500/00 , G01N2500/02 , G01N2500/04 , G01N2800/52 , C12Q2563/131
摘要： A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.
摘要翻译：提供特异性结合剂，其中特异性结合剂特异性结合卡波西肉瘤相关疱疹病毒（KSHV）白细胞介素-6（vIL-6），特异性结合剂中和vIL-6的活性。在一个实施方案中，特异性结合剂是抗体。提供了使用结合vIL-6的特异性结合剂并中和vIL-6的生物学活性的方法。还提供了KSHV相关疾病的治疗方法。提供了用于诊断KSHV相关疾病的方法，以及包括本发明的特异性结合剂的试剂盒。还提供了用于测试试剂以治疗KSHV相关病症的有效性的方法。该方法包括将试剂与包含vIL-6受体组分和vIL-6的无细胞系统一起孵育，并比较在试剂存在下vIL-6和受体组分与vIL-6与受体结合的结合组件在没有代理的情况下。在试剂存在下，vIL-6与受体成分的结合减少表明该试剂对于治疗KSHV相关病症是有效的。

6. 发明授权

US06939547B2 Specific binding agents for KSHV vIL-6 that neutralize a biological activity 失效
标题翻译：用于中和生物活性的KSHV vIL-6的特异性结合剂
公开(公告)号：US06939547B2
公开(公告)日：2005-09-06
申请号：US10333121
申请日：2001-07-31
申请人： Yoshiyasu Aoki , Giovanna Tosato
发明人： Yoshiyasu Aoki , Giovanna Tosato
IPC分类号： A61P31/20 , A61P35/00 , C07K16/08 , C07K16/24 , C12Q1/70 , G01N33/569 , G01N33/68 , A61K39/245
CPC分类号： G01N33/56994 , A61K2039/505 , C07K16/085 , C07K16/248 , C12Q1/705 , G01N33/56983 , G01N33/6869 , G01N2333/03 , G01N2333/5412 , G01N2469/10 , G01N2500/00 , G01N2500/02 , G01N2500/04 , G01N2800/52 , C12Q2563/131
摘要： A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.
摘要翻译：提供特异性结合剂，其中特异性结合剂特异性结合卡波西肉瘤相关疱疹病毒（KSHV）白细胞介素-6（vIL-6），特异性结合剂中和vIL-6的活性。在一个实施方案中，特异性结合剂是抗体。提供了使用结合vIL-6的特异性结合剂并中和vIL-6的生物学活性的方法。还提供了KSHV相关疾病的治疗方法。提供了用于诊断KSHV相关疾病的方法，以及包括本发明的特异性结合剂的试剂盒。还提供了用于测试试剂以治疗KSHV相关病症的有效性的方法。该方法包括将试剂与包含vIL-6受体组分和vIL-6的无细胞系统一起孵育，并比较在试剂存在下vIL-6和受体组分与vIL-6与受体结合的结合组件在没有代理的情况下。在试剂存在下，vIL-6与受体成分的结合减少表明该试剂对于治疗KSHV相关病症是有效的。

7. 发明申请

US20070243162A1 Specific binding agents for KSHV vIL-6 That neutrallize a biological activity 失效
标题翻译： KSHV vIL-6的特异性结合剂使生物活性中和
公开(公告)号：US20070243162A1
公开(公告)日：2007-10-18
申请号：US11803732
申请日：2007-05-14
申请人： Yoshiyasu Aoki , Giovanna Tosato
发明人： Yoshiyasu Aoki , Giovanna Tosato
IPC分类号： A61K38/20 , A61K39/12 , C07K16/08 , C12Q1/70
CPC分类号： G01N33/56994 , A61K2039/505 , C07K16/085 , C07K16/248 , C12Q1/705 , G01N33/56983 , G01N33/6869 , G01N2333/03 , G01N2333/5412 , G01N2469/10 , G01N2500/00 , G01N2500/02 , G01N2500/04 , G01N2800/52 , C12Q2563/131
摘要： A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.
摘要翻译：提供特异性结合剂，其中特异性结合剂特异性结合卡波西肉瘤相关疱疹病毒（KSHV）白细胞介素-6（vIL-6），特异性结合剂中和vIL-6的活性。在一个实施方案中，特异性结合剂是抗体。提供了使用结合vIL-6的特异性结合剂并中和vIL-6的生物学活性的方法。还提供了KSHV相关疾病的治疗方法。提供了用于诊断KSHV相关疾病的方法，以及包括本发明的特异性结合剂的试剂盒。还提供了用于测试试剂以治疗KSHV相关病症的有效性的方法。该方法包括将试剂与包含vIL-6受体组分和vIL-6的无细胞系统一起孵育，并比较在试剂存在下vIL-6和受体组分与vIL-6与受体结合的结合组件在没有代理的情况下。在试剂存在下，vIL-6与受体成分的结合减少表明该试剂对于治疗KSHV相关病症是有效的。

8. 发明申请

US20070015197A1 Specific binding agents for KSHV vIL-6 that neutralize a biological activity 失效
公开(公告)号：US20070015197A1
公开(公告)日：2007-01-18
申请号：US11493687
申请日：2006-07-25
申请人： Yoshiyasu Aoki , Giovanna Tosato
发明人： Yoshiyasu Aoki , Giovanna Tosato
IPC分类号： C12Q1/70 , C12Q1/68
CPC分类号： G01N33/56994 , A61K2039/505 , C07K16/085 , C07K16/248 , C12Q1/705 , G01N33/56983 , G01N33/6869 , G01N2333/03 , G01N2333/5412 , G01N2469/10 , G01N2500/00 , G01N2500/02 , G01N2500/04 , G01N2800/52 , C12Q2563/131
摘要： A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.

9. 发明授权

US07108981B2 Specific binding agents for KSHV vIL-6 that neutralize a biological activity 失效
公开(公告)号：US07108981B2
公开(公告)日：2006-09-19
申请号：US11183336
申请日：2005-07-14
申请人： Yoshiyasu Aoki , Giovanna Tosato
发明人： Yoshiyasu Aoki , Giovanna Tosato
IPC分类号： C12Q1/68
CPC分类号： G01N33/56994 , A61K2039/505 , C07K16/085 , C07K16/248 , C12Q1/705 , G01N33/56983 , G01N33/6869 , G01N2333/03 , G01N2333/5412 , G01N2469/10 , G01N2500/00 , G01N2500/02 , G01N2500/04 , G01N2800/52 , C12Q2563/131
摘要： A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.

10. 发明申请

US20060039927A1 Specific binding agents for KSHV vIL-6 that neutralize a biological activity 失效
标题翻译：用于中和生物活性的KSHV vIL-6的特异性结合剂
公开(公告)号：US20060039927A1
公开(公告)日：2006-02-23
申请号：US11183336
申请日：2005-07-14
申请人： Yoshiyasu Aoki , Giovanna Tosato
发明人： Yoshiyasu Aoki , Giovanna Tosato
IPC分类号： A61K39/27 , C07K16/10
CPC分类号： G01N33/56994 , A61K2039/505 , C07K16/085 , C07K16/248 , C12Q1/705 , G01N33/56983 , G01N33/6869 , G01N2333/03 , G01N2333/5412 , G01N2469/10 , G01N2500/00 , G01N2500/02 , G01N2500/04 , G01N2800/52 , C12Q2563/131
摘要： A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.
摘要翻译：提供特异性结合剂，其中特异性结合剂特异性结合卡波西肉瘤相关疱疹病毒（KSHV）白细胞介素-6（vIL-6），特异性结合剂中和vIL-6的活性。在一个实施方案中，特异性结合剂是抗体。提供了使用结合vIL-6的特异性结合剂并中和vIL-6的生物学活性的方法。还提供了KSHV相关疾病的治疗方法。提供了用于诊断KSHV相关疾病的方法，以及包括本发明的特异性结合剂的试剂盒。还提供了用于测试试剂以治疗KSHV相关病症的有效性的方法。该方法包括将试剂与包含vIL-6受体组分和vIL-6的无细胞系统一起孵育，并比较在试剂存在下vIL-6和受体组分与vIL-6与受体结合的结合组件在没有代理的情况下。在试剂存在下，vIL-6与受体成分的结合减少表明该试剂对于治疗KSHV相关病症是有效的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式